|
Gene: IFI6 |
Gene summary for IFI6 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IFI6 | Gene ID | 2537 |
Gene name | interferon alpha inducible protein 6 | |
Gene Alias | 6-16 | |
Cytomap | 1p35.3 | |
Gene Type | protein-coding | GO ID | GO:0001836 | UniProtAcc | P09912 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2537 | IFI6 | LZE8T | Human | Esophagus | ESCC | 3.94e-05 | 4.75e-01 | 0.067 |
2537 | IFI6 | LZE20T | Human | Esophagus | ESCC | 4.83e-30 | 2.52e+00 | 0.0662 |
2537 | IFI6 | LZE22T | Human | Esophagus | ESCC | 8.10e-09 | 1.59e+00 | 0.068 |
2537 | IFI6 | LZE24T | Human | Esophagus | ESCC | 2.44e-58 | 3.41e+00 | 0.0596 |
2537 | IFI6 | LZE21T | Human | Esophagus | ESCC | 1.70e-03 | 2.16e+00 | 0.0655 |
2537 | IFI6 | LZE6T | Human | Esophagus | ESCC | 1.50e-04 | 7.36e-01 | 0.0845 |
2537 | IFI6 | P1T-E | Human | Esophagus | ESCC | 3.27e-16 | 3.02e+00 | 0.0875 |
2537 | IFI6 | P2T-E | Human | Esophagus | ESCC | 1.25e-120 | 3.68e+00 | 0.1177 |
2537 | IFI6 | P4T-E | Human | Esophagus | ESCC | 9.87e-48 | 1.79e+00 | 0.1323 |
2537 | IFI6 | P5T-E | Human | Esophagus | ESCC | 8.11e-102 | 3.06e+00 | 0.1327 |
2537 | IFI6 | P8T-E | Human | Esophagus | ESCC | 1.88e-88 | 2.97e+00 | 0.0889 |
2537 | IFI6 | P9T-E | Human | Esophagus | ESCC | 2.28e-94 | 3.84e+00 | 0.1131 |
2537 | IFI6 | P10T-E | Human | Esophagus | ESCC | 4.74e-39 | 1.19e+00 | 0.116 |
2537 | IFI6 | P11T-E | Human | Esophagus | ESCC | 1.12e-52 | 4.22e+00 | 0.1426 |
2537 | IFI6 | P12T-E | Human | Esophagus | ESCC | 1.17e-34 | 1.08e+00 | 0.1122 |
2537 | IFI6 | P15T-E | Human | Esophagus | ESCC | 1.83e-67 | 3.02e+00 | 0.1149 |
2537 | IFI6 | P16T-E | Human | Esophagus | ESCC | 6.61e-07 | 5.47e-01 | 0.1153 |
2537 | IFI6 | P17T-E | Human | Esophagus | ESCC | 8.04e-49 | 3.68e+00 | 0.1278 |
2537 | IFI6 | P19T-E | Human | Esophagus | ESCC | 2.88e-10 | 2.95e+00 | 0.1662 |
2537 | IFI6 | P20T-E | Human | Esophagus | ESCC | 1.97e-30 | 2.01e+00 | 0.1124 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123314 | Breast | IDC | regulation of apoptotic signaling pathway | 82/1434 | 356/18723 | 6.27e-20 | 5.93e-17 | 82 |
GO:005254714 | Breast | IDC | regulation of peptidase activity | 96/1434 | 461/18723 | 7.58e-20 | 6.15e-17 | 96 |
GO:009719314 | Breast | IDC | intrinsic apoptotic signaling pathway | 69/1434 | 288/18723 | 6.32e-18 | 2.99e-15 | 69 |
GO:005254814 | Breast | IDC | regulation of endopeptidase activity | 88/1434 | 432/18723 | 1.20e-17 | 4.85e-15 | 88 |
GO:200011614 | Breast | IDC | regulation of cysteine-type endopeptidase activity | 55/1434 | 235/18723 | 4.25e-14 | 1.21e-11 | 55 |
GO:004586114 | Breast | IDC | negative regulation of proteolysis | 70/1434 | 351/18723 | 8.21e-14 | 2.22e-11 | 70 |
GO:004328114 | Breast | IDC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 50/1434 | 209/18723 | 2.49e-13 | 6.14e-11 | 50 |
GO:005134613 | Breast | IDC | negative regulation of hydrolase activity | 71/1434 | 379/18723 | 1.33e-12 | 2.90e-10 | 71 |
GO:001046613 | Breast | IDC | negative regulation of peptidase activity | 56/1434 | 262/18723 | 1.39e-12 | 2.92e-10 | 56 |
GO:200123414 | Breast | IDC | negative regulation of apoptotic signaling pathway | 49/1434 | 224/18723 | 1.45e-11 | 2.58e-09 | 49 |
GO:001095112 | Breast | IDC | negative regulation of endopeptidase activity | 52/1434 | 252/18723 | 3.53e-11 | 5.57e-09 | 52 |
GO:200011713 | Breast | IDC | negative regulation of cysteine-type endopeptidase activity | 25/1434 | 86/18723 | 3.31e-09 | 2.77e-07 | 25 |
GO:000863713 | Breast | IDC | apoptotic mitochondrial changes | 27/1434 | 107/18723 | 2.29e-08 | 1.57e-06 | 27 |
GO:009719114 | Breast | IDC | extrinsic apoptotic signaling pathway | 42/1434 | 219/18723 | 2.56e-08 | 1.73e-06 | 42 |
GO:004315413 | Breast | IDC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 22/1434 | 78/18723 | 5.26e-08 | 3.32e-06 | 22 |
GO:200123614 | Breast | IDC | regulation of extrinsic apoptotic signaling pathway | 32/1434 | 151/18723 | 1.07e-07 | 6.26e-06 | 32 |
GO:000183613 | Breast | IDC | release of cytochrome c from mitochondria | 17/1434 | 59/18723 | 1.23e-06 | 5.44e-05 | 17 |
GO:005188113 | Breast | IDC | regulation of mitochondrial membrane potential | 19/1434 | 74/18723 | 2.04e-06 | 8.27e-05 | 19 |
GO:007259313 | Breast | IDC | reactive oxygen species metabolic process | 36/1434 | 239/18723 | 7.16e-05 | 1.43e-03 | 36 |
GO:200123714 | Breast | IDC | negative regulation of extrinsic apoptotic signaling pathway | 19/1434 | 97/18723 | 1.22e-04 | 2.25e-03 | 19 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFI6 | insertion | Frame_Shift_Ins | novel | c.352_353insT | p.Asn118IlefsTer16 | p.N118Ifs*16 | P09912 | protein_coding | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
IFI6 | insertion | In_Frame_Ins | novel | c.350_351insCACCAA | p.Gly117_Asn118insThrAsn | p.G117_N118insTN | P09912 | protein_coding | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
IFI6 | SNV | Missense_Mutation | novel | c.239N>A | p.Ala80Asp | p.A80D | P09912 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
IFI6 | SNV | Missense_Mutation | novel | c.349N>T | p.Gly117Cys | p.G117C | P09912 | protein_coding | deleterious(0.01) | probably_damaging(0.923) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
IFI6 | SNV | Missense_Mutation | c.50N>T | p.Thr17Ile | p.T17I | P09912 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.525) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
IFI6 | deletion | Frame_Shift_Del | novel | c.48_52delNNNNN | p.Phe16LeufsTer8 | p.F16Lfs*8 | P09912 | protein_coding | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
IFI6 | SNV | Missense_Mutation | novel | c.91N>A | p.Ala31Thr | p.A31T | P09912 | protein_coding | tolerated(0.51) | benign(0.003) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
IFI6 | SNV | Missense_Mutation | novel | c.376N>A | p.Ala126Thr | p.A126T | P09912 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IFI6 | SNV | Missense_Mutation | c.332G>A | p.Gly111Asp | p.G111D | P09912 | protein_coding | deleterious(0) | possibly_damaging(0.8) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IFI6 | SNV | Missense_Mutation | novel | c.44T>C | p.Leu15Pro | p.L15P | P09912 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |